People: Coronado Biosciences Inc (CNDO.PH)
CNDO.PH on Philadelphia Stock Exchange
10.18USD
20 May 2013
10.18USD
20 May 2013
Price Change (% chg)
$0.19 (+1.90%)
$0.19 (+1.90%)
Prev Close
$9.99
$9.99
Open
$10.18
$10.18
Day's High
$10.18
$10.18
Day's Low
$10.18
$10.18
Volume
200
200
Avg. Vol
714
714
52-wk High
$12.40
$12.40
52-wk Low
$4.07
$4.07
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Harlan Weisman |
61 | 2012 | Chairman of the Board, Chief Executive Officer |
Eric Rowinsky |
56 | 2010 | Vice Chairman of the Board |
Lucy Lu |
38 | 2012 | Chief Financial Officer, Executive Vice President |
Noah Beerman |
51 | 2011 | Chief Operating Officer, Executive Vice President |
Karin Hehenberger |
40 | 2012 | Executive Vice President and Chief Medical Officer |
Dale Ritter |
62 | 2011 | Senior Vice President - Finance, Chief Accounting Officer |
David Barrett |
37 | 2011 | Independent Director |
Jimmie Harvey |
61 | 2008 | Independent Director |
J. Jay Lobell |
50 | 2006 | Independent Director |
Michael Rogers |
53 | 2011 | Independent Director |
Lindsay Rosenwald |
58 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Harlan Weisman |
Dr. Harlan F. Weisman, M.D., is Chairman of the Board, Chief Executive Officer of Coronado Biosciences, Inc. Dr. Weisman is the founder and Managing Director of And-One Consulting, LLC, a consulting firm which was formed in March 2012 and focuses on assisting companies to formulate and lead global strategies for accelerating medical product development, regulatory approval and market acceptance. From October 2005 to March 2012, Dr. Weisman was chief science and technology officer of Johnson & Johnson’s Medical Device and Diagnostics business. Dr. Weisman is a graduate of the University of Maryland and the University of Maryland School of Medicine. Dr. Weisman served his residency at Mount Sinai Hospital in New York and was a fellow in cardiovascular disease at Johns Hopkins Hospital. |
Eric Rowinsky |
Dr. Eric K. Rowinsky, M.D., is Vice Chairman of the Board of Coronado Biosciences Inc. Dr. Rowinsky is an internationally in oncology with a distinguished background in academics and industry. Following an oncology fellowship at Johns Hopkins, he became an assistant professor of oncology at Johns Hopkins and then an associate professor at Johns Hopkins. Dr. Rowinsky then became a professor of medicine and director for drug development, cancer therapy and research at University of Texas, San Antonio. In 2004, Dr. Rowinsky became chief medical officer and senior vice president (later promoted to executive vice president) of ImClone Systems, Inc., a cancer therapeutics company, and spear-headed the further clinical development of Erbitux (cetuximab injection) and eight additional monoclonal antibodies, prior to ImClone’s acquisition by Eli Lilly & Company in 2008. He remained at ImClone as a consultant until December 2010. Dr. Rowinsky is and has been a consultant to multiple biotech companies in cancer drug development and serves on the boards of directors of Biogen-Idec Inc., Neoprobe Inc., PreScience Labs Inc., and DLVR, Inc., each of which are life sciences companies. During the past five years, Dr. Rowinsky has also served on the boards of directors of Tapestry Pharmaceuticals, Inc. and Adventrx Pharmaceuticals, Inc., which are life sciences companies. Dr. Rowinsky has been an advisor to academic, industrial and FDA advisory boards and has more than 300 peer-reviewed publications. Dr. Rowinsky received his B.A. from New York University and his M.D. from Vanderbilt University School of Medicine. |
Lucy Lu |
Dr. Lucy Lu, M.D., is Chief Financial Officer, Executive Vice President of Coronado Biosciences Inc. Dr. Lu has over 10 years of experience in the healthcare industry. From February 2007 through January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of the firm in February 2006. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee’s College of Arts and Science. |
Noah Beerman |
Mr. Noah D. Beerman is Chief Operating Officer, Executive Vice President of Coronado Biosciences Inc. Mr. Beerman has over 25 years of experience in the biopharmaceutical industry. Mr. Beerman, who was a consultant to company from May to September 2011, served as president and chief executive officer and a director of Galena Biopharma, Inc., formerly RXi Pharmaceuticals Corporation, from November 2009 until April 2011. Prior to April 2011, he spent more than 10 years at Indevus Pharmaceuticals, Inc., serving most recently as executive vice president and chief business officer from September 2004 until the sale of the company to Endo Pharmaceuticals, Inc. in 2009. Mr. Beerman received an M.B.A. from Northeastern University’s High Technology Program and a B.S. in molecular genetics from the University of Rochester. |
Karin Hehenberger |
Dr. Karin M. Hehenberger, M.D., Ph.D., is Executive Vice President and Chief Medical Officer of Coronado Biosciences Inc. Dr. Hehenberger has over 15 years of experience in the healthcare industry. From January 2010 until joining company, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation, or JDRF, where she was responsible for advancing JDRF’s involvement with scientific, financial, and commercial partners in the diabetes community. From February 2008 until January 2010, she served as Vice President of Metabolic Strategy and Business Development at Johnson & Johnson. From October 2005 through February 2008, Dr. Hehenberger served as Senior Investment Director and Partner at Scandinavian Life Science Venture. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School. |
Dale Ritter |
Mr. Dale Ritter is Senior Vice President - Finance, Chief Accounting Officer of Coronado Biosciences Inc. Mr. Ritter has over 20 years of experience in the pharmaceutical industry. From September 2009 until joining the company in May 2011, he was an independent consultant, serving as a financial consultant to Helicos BioSciences Corporation, an innovative genetic analysis technologies company. From 1994 to 2009, Mr. Ritter was the senior vice president of finance and chief accounting officer at Indevus Pharmaceuticals until the sale of the company to Endo Pharmaceuticals. Mr. Ritter has a B.A. from Syracuse University and an M.B.A. from Babson College Graduate School of Business Administration. |
David Barrett |
Mr. David J. Barrett is Independent Director of Coronado Biosciences Inc. In July 2010, after transitioning from Neuro-Hitech, Inc., Mr. Barrett became the chief financial officer of Ventrus Biosciences, Inc., a pharmaceutical company focused on the late-stage clinical development of gastrointestinal products. From April 2006 to September 2009, Mr. Barrett served as chief financial officer of Neuro-Hitech, Inc., a publicly traded company focused on developing, marketing and distributing branded and generic pharmaceutical products. From September 2003 to April 2006, Mr. Barrett was the chief financial officer/vice president of finance of Overture Asset Managers and Overture Financial Services, which, at the time, was a start-up asset management firm that assembled investment products and platforms to distribute turnkey and unbundled investment solutions to financial intermediaries and institutional investors. From July 1999 to September 2003, Mr. Barrett was employed as a manager at Deloitte & Touche, LLP. Mr. Barrett received his B.S. in accounting and economics in May 1998 and his M.S. in accounting in May 1999 from the University of Florida. He is a certified public accountant. |
Jimmie Harvey |
Dr. Jimmie Harvey, Jr., M.D., is Independent Director of Coronado Biosciences Inc. Dr. Harvey in 1984 founded Birmingham Hematology and Oncology Associates L.L.C., a private medical company located in Birmingham, Alabama. Dr. Harvey has experience in clinical trial execution and management and has recently been a principal investigator in two trials, one investigating a novel monoclonal antibody and the other a small molecule used to treat immunologic malignancies. Dr. Harvey holds a B.A. degree in Chemistry from Emory University and received his M.D. from Emory University School of Medicine. Dr. Harvey completed his medical oncology training at the Vincent T. Lombardi Cancer Center at Georgetown University. |
J. Jay Lobell |
Mr. J. Jay Lobell is Independent Director of Coronado Biosciences Inc. Mr. Lobell is president of Meridian Capital Group, LLC, a commercial real estate mortgage company, which he joined as a senior officer in January 2010. Mr. Lobell also is a founder of, and since December 2009 has served as vice chairman of, Beech Street Capital, LLC, a real estate lending company. Since January 2005, Mr. Lobell has served as president and chief operating officer of Paramount Biosciences, LLC, or PBS, a biotechnology investment and development company. In that capacity, he had substantial responsibility for the assembly and oversight of companies founded and incubated by PBS, including Coronado and Asphelia. Mr. Lobell previously has served on the board of directors of NovaDel Pharma Inc., Innovive Pharmaceuticals, Inc. and ChemRx Corporation. Mr. Lobell was a partner in the law firm Covington & Burling LLP from October 1996 through January 2005, where he advised companies and individuals as a member of the firm’s securities litigation and white collar defense practice group. Mr. Lobell received his B.A. (summa cum laude, Phi Beta Kappa) from the City University of New York and his J.D. from Yale Law School, where he was senior editor of the Yale Law Journal. |
Michael Rogers |
Mr. Michael W. Rogers is Independent Director of Coronado Biosciences Inc. From June 2009 to October 2012, Mr. Rogers served as the executive vice president, chief financial officer and treasurer of BG Medicine, Inc., a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests. Prior to joining BG Medicine, Inc. and since 1999, Mr. Rogers held the position of executive vice president, chief financial officer and treasurer at Indevus Pharmaceuticals, Inc., a specialty pharmaceuticals company, which was acquired by Endo Pharmaceuticals in 2009. In 1998, Mr. Rogers was executive vice president and chief financial and corporate development officer at Advanced Health Corporation, a publicly traded healthcare information technology company. From 1995 to 1997, he was vice president, chief financial officer and treasurer of AutoImmune, Inc., a publicly-traded biopharmaceutical company. From 1994 to 1995, Mr. Rogers was vice president, investment banking at Lehman Brothers, Inc. From 1990 to 1994, he was associated with PaineWebber, Inc., serving most recently as vice president, investment banking division. Mr. Rogers serves as a director of pSivida, Inc., a publicly-traded medical device company. Mr. Rogers received an M.B.A. from the Darden School at the University of Virginia and a B.A. from Union College. |
Lindsay Rosenwald |
Dr. Lindsay A. Rosenwald, M.D., is Independent Director of Coronado Biosciences Inc. Since November 2008, Dr. Rosenwald has served as Co-Portfolio Manager & Partner of Opus Point Partners, LLC, or Opus, an asset management and broker dealer in the life sciences industry. Prior to that, from August 1991 to October 2008, he served as the Chairman of Paramount BioCapital, Inc., or PBC. Over the last 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and been instrumental in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Harlan Weisman |
137,990 |
Eric Rowinsky |
-- |
Lucy Lu |
1,873,350 |
Noah Beerman |
464,660 |
Karin Hehenberger |
1,172,570 |
Dale Ritter |
582,568 |
David Barrett |
-- |
Jimmie Harvey |
-- |
J. Jay Lobell |
-- |
Michael Rogers |
-- |
Lindsay Rosenwald |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Harlan Weisman |
0 | 0 |
Eric Rowinsky |
0 | 0 |
Lucy Lu |
0 | 0 |
Noah Beerman |
0 | 0 |
Karin Hehenberger |
0 | 0 |
Dale Ritter |
0 | 0 |
David Barrett |
0 | 0 |
Jimmie Harvey |
0 | 0 |
J. Jay Lobell |
0 | 0 |
Michael Rogers |
0 | 0 |
Lindsay Rosenwald |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SANDAGE BOBBY W JR |
3,000 | $0.00 |
WEISMAN HARLAN F |
20,000 | $5.71 |
SANDAGE BOBBY W JR |
3,811 | $4.02 |
COOPER GLENN L |
3,811 | $4.02 |
SANDAGE BOBBY W JR |
10,000 | $5.00 |
RITTER DALE |
5,000 | $5.00 |
ROSENWALD LINDSAY A |
200,000 | $5.00 |
HEHENBERGER KARIN M |
20,000 | $5.00 |
COOPER GLENN L |
10,000 | $5.30 |
BEERMAN NOAH D |
5,000 | $5.00 |
LU LUCY |
10,000 | $5.00 |
LOBELL JONAH JAY |
25,000 | $5.00 |
ROSENWALD LINDSAY A |
2,000 | $6.95 |
ROSENWALD LINDSAY A |
2,000 | $5.66 |
ROSENWALD LINDSAY A |
2,000 | $5.67 |
ROSENWALD LINDSAY A |
2,000 | $5.66 |
ROSENWALD LINDSAY A |
2,000 | $5.40 |
ROSENWALD LINDSAY A |
2,000 | $5.40 |
SANDAGE BOBBY W JR |
1,000 | $5.20 |
ROSENWALD LINDSAY A |
2,000 | $5.20 |
BEERMAN NOAH D |
5,000 | $4.99 |
ROSENWALD LINDSAY A |
2,000 | $5.49 |
SANDAGE BOBBY W JR |
500 | $5.28 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
